Faricimab Treat-and-Extend for Diabetic Macular Edema

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

New England Journal of Medicine · 2015 · 1.5K citations · Full text

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

John A. Wells, Adam R. Glassman, Allison R. Ayala et al. · Ophthalmology · 2016 · 982 citations · Full text

Diabetic Retinopathy, Ocular Disease, Ophthalmology +4

Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation

Ulrike Fiedler, Yvonne Reiss, Marion Scharpfenecker et al. · Nature Medicine · 2006 · 896 citations

Inflammation, Endothelial Cell Pathobiology, Cytokine +14

Diabetic Retinopathy Preferred Practice Pattern®

Christina J. Flaxel, Ron A. Adelman, Steven T. Bailey et al. · Ophthalmology · 2019 · 659 citations

Diabetic Retinopathy, Ocular Disease, Ophthalmology +2

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

The Lancet · 2022 · 605 citations · Full text

Ocular Disease, Vitreous Body, Ophthalmology +6